5 Notable FDA Approvals From the First Half of 2026
• The FDA approved five first-in-class therapies during the first half of 2026, targeting obesity, AML, kidney disease, hearing loss, and bladder cancer. • On April 14, Travere Therapeutics received approval for sparsentan (Filspari), the first treatment specifically approved for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. • These approvals are significant as they replace off-label or burdensome parenteral treatments with more accessible options, such as all-oral regimens that allow patients to be treated at home.
ajmc.com




